Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors

Hiroki Yabe, Tomohide Tsukahara, Satoshi Kawaguchi, Takuro Wada, Toshihiko Torigoe, Noriyuki Sato, Chihiro Terai, Masaya Aoki, Shigemichi Hirose, Hideo Morioka, Hiroo Yabe

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T-cell infiltration has yet to be reported. Methods: Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti-HLA class I monoclonal antibody (mAb) EMR8-5 and anti-CD8 mAb, respectively. Results: Expression of HLA class I was negative in 10 tumors and down-regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down-regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients. Conclusions: Our results suggested that CD8+ T cell-mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT.

Original languageEnglish
Pages (from-to)380-385
Number of pages6
JournalJournal of Surgical Oncology
Volume103
Issue number5
DOIs
Publication statusPublished - 2011 Apr

Fingerprint

Ewing's Sarcoma
HLA Antigens
Neoplasms
T-Lymphocytes
Monoclonal Antibodies
Survival
Immunohistochemistry
Biopsy
Peptides

Keywords

  • CD8
  • ESFT
  • Ewing's
  • Hla class I
  • Sarcoma
  • T lymphocyte

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Yabe, H., Tsukahara, T., Kawaguchi, S., Wada, T., Torigoe, T., Sato, N., ... Yabe, H. (2011). Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors. Journal of Surgical Oncology, 103(5), 380-385. https://doi.org/10.1002/jso.21829

Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors. / Yabe, Hiroki; Tsukahara, Tomohide; Kawaguchi, Satoshi; Wada, Takuro; Torigoe, Toshihiko; Sato, Noriyuki; Terai, Chihiro; Aoki, Masaya; Hirose, Shigemichi; Morioka, Hideo; Yabe, Hiroo.

In: Journal of Surgical Oncology, Vol. 103, No. 5, 04.2011, p. 380-385.

Research output: Contribution to journalArticle

Yabe, H, Tsukahara, T, Kawaguchi, S, Wada, T, Torigoe, T, Sato, N, Terai, C, Aoki, M, Hirose, S, Morioka, H & Yabe, H 2011, 'Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors', Journal of Surgical Oncology, vol. 103, no. 5, pp. 380-385. https://doi.org/10.1002/jso.21829
Yabe, Hiroki ; Tsukahara, Tomohide ; Kawaguchi, Satoshi ; Wada, Takuro ; Torigoe, Toshihiko ; Sato, Noriyuki ; Terai, Chihiro ; Aoki, Masaya ; Hirose, Shigemichi ; Morioka, Hideo ; Yabe, Hiroo. / Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors. In: Journal of Surgical Oncology. 2011 ; Vol. 103, No. 5. pp. 380-385.
@article{e1d0ec5d4e854da0a665fbef488eff9d,
title = "Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors",
abstract = "Background: Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T-cell infiltration has yet to be reported. Methods: Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti-HLA class I monoclonal antibody (mAb) EMR8-5 and anti-CD8 mAb, respectively. Results: Expression of HLA class I was negative in 10 tumors and down-regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down-regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients. Conclusions: Our results suggested that CD8+ T cell-mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT.",
keywords = "CD8, ESFT, Ewing's, Hla class I, Sarcoma, T lymphocyte",
author = "Hiroki Yabe and Tomohide Tsukahara and Satoshi Kawaguchi and Takuro Wada and Toshihiko Torigoe and Noriyuki Sato and Chihiro Terai and Masaya Aoki and Shigemichi Hirose and Hideo Morioka and Hiroo Yabe",
year = "2011",
month = "4",
doi = "10.1002/jso.21829",
language = "English",
volume = "103",
pages = "380--385",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Prognostic significance of HLA class I expression in Ewing's sarcoma family of tumors

AU - Yabe, Hiroki

AU - Tsukahara, Tomohide

AU - Kawaguchi, Satoshi

AU - Wada, Takuro

AU - Torigoe, Toshihiko

AU - Sato, Noriyuki

AU - Terai, Chihiro

AU - Aoki, Masaya

AU - Hirose, Shigemichi

AU - Morioka, Hideo

AU - Yabe, Hiroo

PY - 2011/4

Y1 - 2011/4

N2 - Background: Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T-cell infiltration has yet to be reported. Methods: Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti-HLA class I monoclonal antibody (mAb) EMR8-5 and anti-CD8 mAb, respectively. Results: Expression of HLA class I was negative in 10 tumors and down-regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down-regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients. Conclusions: Our results suggested that CD8+ T cell-mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT.

AB - Background: Ewing's sarcoma family of tumors (ESFT) is one of the most malignant groups of tumors in young people. Human leukocyte antigen (HLA) class I displays endogenously processed peptides to CD8+ T lymphocytes and has a key role for host immune surveillance. In ESFT, the investigation concerning both HLA class I expression and T-cell infiltration has yet to be reported. Methods: Biopsy specimens from 28 ESFT patients were evaluated by immunohistochemistry with the anti-HLA class I monoclonal antibody (mAb) EMR8-5 and anti-CD8 mAb, respectively. Results: Expression of HLA class I was negative in 10 tumors and down-regulated in 22 tumors. The status of CD8+ T cell infiltration was closely associated with the expression levels of HLA class I. ESFT patients with down-regulated or negative expression of HLA class I showed significantly poorer survival than the rest of the patients. Conclusions: Our results suggested that CD8+ T cell-mediated immune response restricted by HLA class I might play an important role in immune surveillance of ESFT, and we revealed for the first time that the status of HLA class I expression affects the survival of the patients with ESFT.

KW - CD8

KW - ESFT

KW - Ewing's

KW - Hla class I

KW - Sarcoma

KW - T lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=79952584804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952584804&partnerID=8YFLogxK

U2 - 10.1002/jso.21829

DO - 10.1002/jso.21829

M3 - Article

C2 - 21400519

AN - SCOPUS:79952584804

VL - 103

SP - 380

EP - 385

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 5

ER -